Also known as: Cabometyx, Cometriq (brand)
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR-1/2/3, MET, AXL, and RET. It is approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Mediocon Inc supplies pharmaceutical-grade Cabozantinib tablets and API meeting IP/BP/EP/USP standards.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Strength | 60 mg tablets |
| Assay | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Storage | Store below 30°C |
| Microbial Limits | Complies with pharmacopoeia |
| Packing | 30×1×60 Tablets per drum |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Cabozantinib (CAS 849217-68-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Cabozantinib is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance